Peptide Knowledge Base · Metabolic
Retatrutide: what it is, what the evidence says, and its real status
An investigational triple GLP-1/GIP/glucagon agonist posting the largest weight-loss numbers recorded so far.
Short version: the molecule the metabolic world is watching hardest. Phase-3 trial figures lead the category, but it is investigational, not approved, and not something anyone can legitimately get yet.
Can you actually get it?
Plain-English verdict: Waitlist / education.
Regulatory status: Investigational (Phase 3) · Not yet approved.
Not available to prescribe. Retatrutide is an investigational drug in Phase-3 trials (Eli Lilly), not FDA-approved, not compoundable, and heavily counterfeited on the grey market. We track it and capture demand honestly; we make no availability promise.
How does Retatrutide work?
A single molecule agonizing three receptors, GLP-1, GIP, and glucagon, combining appetite suppression with an added energy-expenditure signal from glucagon.
What it does — and what it does not do
What it does: In trials, drives the largest average body-weight reduction seen to date for the class (reported ~24–29%).
What it does not do: It is not approved, not available, and not a guaranteed result; trial figures are not a promise and grey-market product is unverified and unsafe.
How honest is the evidence?
Evidence grade B — large Phase-3 trial data (TRIUMPH), figures pending peer review; re-verify. Read our grading methodology for what each grade means.
What we still don't know: Long-term safety and durability are not yet established; the trial program is ongoing and figures may change at peer review and approval.
WADA status: Not prohibited.
How it is taken
What the literature reports: subcutaneous, weekly, titrated. Educational only, no dose figures, never an instruction to self-administer.
Who should not take it
Investigational, full safety profile not characterized. Medullary thyroid carcinoma / MEN-2 signal class-wide; pregnancy. Clinician-gated.
Sources
Jastreboff et al., retatrutide Phase-2 (NEJM 2023) · TRIUMPH Phase-3 program (ongoing, re-verify against primary sources)
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.